Phase II Trial of Aminopterin in Patients With Persistent or Recurrent Endometrial Carcinoma
OBJECTIVES: I. Estimate the antitumor activity of aminopterin in patients with persistent,
recurrent, or refractory endometrial carcinoma who have failed prior first line cytotoxic
chemotherapy. II. Determine the quantitative and qualitative toxic effects of aminopterin in
this patient population. III. Determine the overall patient survival and time to progression
of these patients. IV. Assess the pharmacokinetic profile of these patients.
OUTLINE: Patients receive oral aminopterin every 12 hours twice weekly. Treatment continues
for up to 15 months in the absence of disease progression or unacceptable toxicity. Patients
are followed every 3 months until death.
PROJECTED ACCRUAL: A total of 15-25 patients will be accrued for this study.
Primary Purpose: Treatment
David S. Miller, MD
Simmons Cancer Center
United States: Federal Government
|Simmons Cancer Center - Dallas||Dallas, Texas 75235-9154|
|East Carolina University School of Medicine||Greenville, North Carolina 27858-4354|
|University of Wisconsin Comprehensive Cancer Center||Madison, Wisconsin 53792|
|Texas Oncology, P.A.||Dallas, Texas 75246|
|Division of Gynecologic Oncology||Saint Louis, Missouri 63110|
|Gynecologic Oncologists of NE Ohio||Akron, Ohio 44302|